VIR

#2065
Vir Biotechnology, Inc. - Common Stock
10.7 8 USD
0.00%
Market Price
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
10.70
11.17
Yıllık Aralık
4.81
11.50
Günlük Değişim
-0.46%
Aylık Değişim
+23.34%
6 Aylık Değişim
+21.81%
Yıllık Değişim
+80.27%
Önceki Kapanış
10.8 3
Open
11.0 8
Düşük
10.7 0
Yüksek
11.1 7
Hacim
1 228
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Temettüler Documents

2026

Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Vir Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Vir Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K

Vir Biotechnology, Inc. current report, Q2 FY2024

Full document

Vir Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. on June 26, 2024. The filing reports a significant regulatory milestone regarding the Company's investigational drug combination for chronic hepatitis delta infection.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As a Form 8-K reporting a specific event, it focuses on regulatory status rather than periodic financial performance.

Material Changes and Events

  • FDA Clearance: The U.S. Food and Drug Administration (FDA) cleared the investigational new drug application for the combination of tobevibart and elebsiran.
  • Fast Track Designation: The FDA granted Fast Track designation for the tobevibart and elebsiran combination for the treatment of chronic hepatitis delta infection.
  • Program Focus: The event pertains specifically to the Company's chronic hepatitis delta and chronic hepatitis B programs.

Guidance, Outlook, and Risks

Management commentary is limited to the announcement of the regulatory clearance and designation. The filing includes extensive forward-looking statements regarding the potential clinical effects, safety, efficacy, and timing of data releases for ongoing trials, including the Phase 2 SOLSTICE data.

Key Risks and Contingencies:

  • Fast Track designation does not guarantee marketing approval or expedite the review process.
  • The FDA may later determine the combination no longer meets qualification conditions.
  • Drug development involves high risk; early-stage trial results may not predict later-stage outcomes.
  • Potential for unexpected safety events, efficacy data issues, costs, delays, or geopolitical disruptions.

Investor Verification Checklist

  • Verify the specific terms of the Fast Track designation and its impact on the regulatory timeline.
  • Review the full text of the press release (Exhibit 99.1) for details on the tobevibart and elebsiran mechanism of action.
  • Monitor upcoming data readouts from the Phase 2 SOLSTICE trial and other ongoing studies.
  • Assess the Company's cash runway and capital requirements in subsequent periodic filings (10-Q/10-K), as this 8-K does not provide liquidity data.

Haberler